Supernus Pharmaceuticals Share Price Today
(NASDAQ: SUPN)

Name: Supernus Pharmaceuticals Share Price Today (NASDAQ: SUPN) - Supernus Pharmaceuticals Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Supernus Pharmaceuticals share price is $39.11 & ₹3,394.32 as on 15 Feb 2025, 2.30 'hrs' IST

$39.11

▲

-0.42

(-1.06%)

Market is closed - opens 8 PM, 18 Feb 2025

View live Supernus Pharmaceuticals share price in Dollar and Rupees. Guide to invest in Supernus Pharmaceuticals stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Supernus Pharmaceuticals, along with analyst recommendations, forecasts, and comprehensive financials.

Supernus Pharmaceuticals share price movements

Today's Low: $39.06
Today's High: $39.59
$39.11
0.13%
Downside
Day's Volatility :1.33%
Upside
1.21%
52 Weeks Low: $25.53
52 Weeks High: $40.28
$39.11
34.72%
Downside
52 Weeks Volatility :36.62%
Upside
2.9%

Supernus Pharmaceuticals (SUPN) Returns

Period	Supernus Pharmaceuticals Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	10.95%	2.1%	0.0%
6 Months	14.32%	-5.2%	0.0%
1 Year	37.61%	-0.2%	0.0%
3 Years	26.82%	11.1%	-14.8%

Supernus Pharmaceuticals (SUPN) Key Statistics

in dollars & INR

Previous Close	$39.53
Open	$39.59
Today's High	$39.5872
Today's Low	$39.06
Market Capitalization	$2.2B
Today's Volume	$326.5K
52 Week High	$40.28
52 Week Low	$25.53
Revenue TTM	$652.0M
EBITDA	$144.0M
Earnings Per Share (EPS)	$1.06
PE Ratio	36.9
Profit Margin	9.16%
Quarterly Earnings Growth YOY	-0.99%
Return On Equity TTM	6.22%

How to invest in Supernus Pharmaceuticals Stock (SUPN) from India?

It is very easy for Indian residents to invest directly in Supernus Pharmaceuticals from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Supernus Pharmaceuticals stock in both Indian Rupees (INR) and US Dollars (USD). Search for Supernus Pharmaceuticals or SUPN on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Supernus Pharmaceuticals or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Supernus Pharmaceuticals shares which would translate to 0.022 fractional shares of Supernus Pharmaceuticals as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Supernus Pharmaceuticals, in just a few clicks!

Returns in Supernus Pharmaceuticals (SUPN) for Indian investors in Rupees

The Supernus Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Supernus Pharmaceuticals investment value today

Current value as on today

₹1,42,176

Returns

₹42,176

(+42.18%)

Returns from Supernus Pharmaceuticals Stock

₹37,614 (+37.61%)

Dollar Returns

₹4,561 (+4.56%)

Indian investors sentiment towards Supernus Pharmaceuticals (SUPN)

-28%

Period: Jan 15, 2025 to Feb 14, 2025. Change in 30 Days versus previous period

Search interest for Supernus Pharmaceuticals Stock from India on INDmoney has decreased by -28% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Supernus Pharmaceuticals

BlackRock Inc
18.23%
Vanguard Group Inc
11.10%
Armistice Capital, LLC
9.23%
Dimensional Fund Advisors, Inc.
5.22%
Macquarie Group Ltd
4.77%
State Street Corp
3.91%

Analyst Recommendation on Supernus Pharmaceuticals

Buy

80%Buy

20%Hold

0%Sell

Based on 10 Wall street analysts offering stock ratings for Supernus Pharmaceuticals(by analysts ranked 0 to 5 stars)

Based on 10 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Supernus Pharmaceuticals Stock (SUPN)

What analysts predicted

Upside of 9.95%

Target:

$43.00

Current:

$39.11

Insights on Supernus Pharmaceuticals Stock (Ticker Symbol: SUPN)

Price Movement
In the last 1 year, SUPN stock has moved up by 36.5%
Increasing Revenue
Revenue is up for the last 3 quarters, 143.64M → 175.68M (in $), with an average increase of 9.4% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, 124.0K → 38.49M (in $), with an average increase of 73.8% per quarter
SUPN vs ITCI (1 yr)
In the last 1 year, Intra-cellular Therapies, Inc. has given 70.7% return, outperforming this stock by 34.2%
SUPN vs ITCI (3 yr)
In the last 3 years, Intra-cellular Therapies, Inc. has given 128.2% return, outperforming this stock by 100.2%
Price to Sales
ForSUPN every $1 of sales, investors are willing to pay $3.3, whereas for Intra-cellular Therapies, Inc., the investors are paying $21.0 for every $1 of sales.

SUPN Supernus Pharmaceuticals Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$408.9M	↑ 35.29%
Net Income	$111.0M	↑ 93.76%
Net Profit Margin	27.14%	↑ 8.19%

	FY19	Y/Y Change
Revenue	$392.8M	↓ 3.95%
Net Income	$113.1M	↑ 1.86%
Net Profit Margin	28.79%	↑ 1.65%

	FY20	Y/Y Change
Revenue	$520.4M	↑ 32.5%
Net Income	$127.0M	↑ 12.29%
Net Profit Margin	24.39%	↓ 4.4%

	FY21	Y/Y Change
Revenue	$579.8M	↑ 11.41%
Net Income	$53.4M	↓ 57.92%
Net Profit Margin	9.21%	↓ 15.18%

	FY22	Y/Y Change
Revenue	$667.2M	↑ 15.09%
Net Income	$60.7M	↑ 13.64%
Net Profit Margin	9.1%	↓ 0.11%

	FY23	Y/Y Change
Revenue	$607.5M	↓ 8.95%
Net Income	$1.3M	↓ 97.83%
Net Profit Margin	0.22%	↓ 8.88%

	Q2 FY23	Q/Q Change
Revenue	$135.6M	↓ 11.84%
Net Income	$-831.0K	↓ 104.9%
Net Profit Margin	-0.61%	↓ 11.63%

	Q3 FY23	Q/Q Change
Revenue	$153.9M	↑ 13.51%
Net Income	$-16.0M	↑ 1822.5%
Net Profit Margin	-10.38%	↓ 9.77%

	Q4 FY23	Q/Q Change
Revenue	$164.3M	↑ 6.78%
Net Income	$1.2M	↓ 107.35%
Net Profit Margin	0.72%	↑ 11.1%

	Q1 FY24	Q/Q Change
Revenue	$143.6M	↓ 12.58%
Net Income	$124.0K	↓ 89.45%
Net Profit Margin	0.09%	↓ 0.63%

	Q2 FY24	Q/Q Change
Revenue	$168.3M	↑ 17.18%
Net Income	$19.9M	↑ 15961.29%
Net Profit Margin	11.83%	↑ 11.74%

	Q3 FY24	Q/Q Change
Revenue	$175.7M	↑ 4.37%
Net Income	$38.5M	↑ 93.3%
Net Profit Margin	21.91%	↑ 10.08%

	FY18	Y/Y Change
Profit	$393.5M	↑ 37.11%

	FY19	Y/Y Change
Profit	$376.1M	↓ 4.43%

	FY20	Y/Y Change
Profit	$467.9M	↑ 24.42%

	FY21	Y/Y Change
Profit	$504.7M	↑ 7.86%

	FY22	Y/Y Change
Profit	$580.0M	↑ 14.92%

	FY23	Y/Y Change
Profit	$523.7M	↓ 9.7%

	Q2 FY23	Q/Q Change
Profit	$114.5M	↓ 12.15%

	Q3 FY23	Q/Q Change
Profit	$134.3M	↑ 17.3%

	Q4 FY23	Q/Q Change
Profit	$123.0M	↓ 8.39%

	Q1 FY24	Q/Q Change
Profit	$106.6M	↓ 13.35%

	Q2 FY24	Q/Q Change
Profit	$129.7M	↑ 21.69%

	Q3 FY24	Q/Q Change
Profit	$138.0M	↑ 6.41%

	FY18	Y/Y Change
Operating Cash Flow	$129.0M	↑ 12.51%
Investing Cash Flow	$-413.5M	↑ 378.48%
Financing Cash Flow	$376.4M	↑ 6526.26%

	FY19	Y/Y Change
Operating Cash Flow	$143.1M	↑ 10.96%
Investing Cash Flow	$-157.9M	↓ 61.81%
Financing Cash Flow	$3.9M	↓ 98.96%

	FY20	Y/Y Change
Operating Cash Flow	$138.4M	↓ 3.3%
Investing Cash Flow	$-34.7M	↓ 78.03%
Financing Cash Flow	$3.6M	↓ 9.39%

	FY21	Y/Y Change
Operating Cash Flow	$127.1M	↓ 8.14%
Investing Cash Flow	$-81.9M	↑ 136.07%
Financing Cash Flow	$-130.4M	↓ 3764.51%

	FY22	Y/Y Change
Operating Cash Flow	$116.8M	↓ 8.1%
Investing Cash Flow	$-216.7M	↑ 164.5%
Financing Cash Flow	$-10.5M	↓ 91.97%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-18.9M	↓ 138.42%
Investing Cash Flow	$60.3M	↓ 74.85%
Financing Cash Flow	$-478.9M	↓ 697.35%

Supernus Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Supernus Pharmaceuticals is currently in a neutral trading position according to technical analysis indicators.

Supernus Pharmaceuticals (SUPN) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Supernus Pharmaceuticals Inc	3.27%	14.32%	37.61%	26.82%	66.0%
Intra-cellular Therapies, Inc.	1.24%	68.78%	68.96%	129.03%	433.92%
Haleon Plc Spon Ads	5.66%	-0.61%	18.13%	31.04%	31.04%
Zoetis Inc.	-7.0%	-14.61%	-16.39%	-19.26%	9.66%
Neurocrine Biosciences Inc.	-18.95%	-22.41%	-13.07%	33.95%	9.8%
Viatris Inc.	-4.76%	-8.71%	-17.3%	-29.18%	-33.9%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Supernus Pharmaceuticals Inc	36.9	36.9	1.47	2.87	0.06	0.03	NA	18.24
Intra-cellular Therapies, Inc.	NA	NA	0.0	-0.71	-0.1	-0.07	NA	10.8
Haleon Plc Spon Ads	30.34	30.34	1.76	0.36	0.07	0.04	0.02	1.82
Zoetis Inc.	30.12	30.12	2.57	6.15	0.49	0.15	0.01	11.59
Neurocrine Biosciences Inc.	35.5	35.5	0.37	6.45	0.14	0.1	NA	26.05
Viatris Inc.	224.4	NA	0.07	2.68	-0.04	0.02	0.04	16.58

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Supernus Pharmaceuticals Inc	Buy	$2.2B	66.0%	36.9	9.16%
Intra-cellular Therapies, Inc.	Buy	$13.6B	433.92%	NA	-14.07%
Haleon Plc Spon Ads	Buy	$44.1B	31.04%	30.34	10.75%
Zoetis Inc.	Buy	$74.4B	9.66%	30.12	26.86%
Neurocrine Biosciences Inc.	Buy	$11.7B	9.8%	35.5	14.49%
Viatris Inc.	Hold	$12.9B	-33.9%	224.4	-5.87%

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

Organization	Supernus Pharmaceuticals
Employees	652
CEO	Mr. Jack A. Khattar M.B.A.
Industry	Health Technology

Management People of Supernus Pharmaceuticals

Name	Title
Mr. Jack A. Khattar M.B.A.	Founder, President, CEO, Secretary & Director
Mr. Timothy C. Dec	Senior VP & CFO
Dr. Padmanabh P. Bhatt Ph.D.	Chief Scientific Officer & Senior VP of Intellectual Property
Mr. Frank Mottola	Senior Vice President of Quality, GMP Operations, Information Technology and Regulatory Affairs
Dr. Jonathan Rubin M.B.A., M.D.	Senior VP of Research & Development and Chief Medical Officer
Mr. Kevin T. Anderson Esq.	Compliance Officer
Dr. Todd Horich M.B.A., Ph.D.	Senior Vice President of Marketing, Commercial Operations & Market Access
Mr. Taylor Raiford	Senior Vice President of Sales
Dr. Bryan A. Roecklein Ph.D.	Senior Vice President of Corporate Development
Mr. Jeff Bozick	Senior Vice President of Supply Chain

Important FAQs about investing in SUPN Stock from India :

What is Supernus Pharmaceuticals share price today?

Supernus Pharmaceuticals share price today stands at $39.11, Open: $39.59 ; Previous Close: $39.53 ; High: $39.59 ; Low: $39.06 ; 52 Week High: $40.28 ; 52 Week Low: $25.53.

The stock opens at $39.59, after a previous close of $39.53. The stock reached a daily high of $39.59 and a low of $39.06, with a 52-week high of $40.28 and a 52-week low of $25.53.

Can Indians buy Supernus Pharmaceuticals shares?

Yes, Indians can invest in the Supernus Pharmaceuticals (SUPN) from India.

With INDmoney, you can buy Supernus Pharmaceuticals at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Supernus Pharmaceuticals at zero transaction cost.

How can I buy Supernus Pharmaceuticals shares from India?

It is very easy to buy Supernus Pharmaceuticals from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Supernus Pharmaceuticals (SUPN) be purchased?

Yes, you can buy fractional shares of Supernus Pharmaceuticals with INDmoney app.

What are the documents required to start investing in Supernus Pharmaceuticals stocks?

To start investing in Supernus Pharmaceuticals, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.